Dr. Reddy's Starts Year on Weak Ground as Lenalidomide and Semaglutide Impacts Weigh on Results

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. Global generics make up roughly 90% of the firm's revenue, and along with other generics manufacturers, the segment suffers low- to mid-single-digit price erosion year over year in developed markets like North America and the majority of Europe. Because headwinds exist predominantly in small-molecule oral tablets that are easy to produce and face stiff competition, the firm has shifted its pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or modes of administration. They are more difficult to manufacture which by nature limits competition. We think about 30% of Reddy's North American sales comes from complex injectables, a figure we expect to increase as the firm continues to prioritize these offerings and reinvest in its pipeline.